Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 14/20 | 1.00 |
| ▸ | MMP13 | P45452 | 6/20 | 0.71 |
| ▸ | MMP8 | P22894 | 2/20 | 0.71 |
| ▸ | MMP2 | P08253 | 1/20 | 0.71 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12708191 | 0.89 | ADAM17 (1.00) | ADAM17MMP13MMP8MMP2KDM4E | |
| SCHEMBL12708205 | 0.88 | ADAM17 (0.81) | ADAM17MMP13MMP8MMP2MMP1 | |
| SCHEMBL8329165 | 0.83 | ADAM17 (1.00) | ADAM17MMP13MMP8MMP2MMP1 | |
| SCHEMBL12708189 | 0.83 | ADAM17 (1.00) | ADAM17MMP13MMP8MMP2MMP1 | |
| SCHEMBL8334970 | 0.83 | ADAM17 (1.00) | ADAM17MMP13MMP8MMP2MMP1 | |
| SCHEMBL12708193 | 0.78 | ADAM17 (0.73) | ADAM17MMP13MMP8MMP2ALDH1A1 | |
| SCHEMBL12730569 | 0.77 | ADAM17 (0.71) | ADAM17MMP13MMP8MMP2ALDH1A1 | |
| SCHEMBL8334686 | 0.77 | ADAM17 (0.71) | ADAM17MMP13MMP8MMP2ALDH1A1 | |
| SCHEMBL12730849 | 0.77 | ADAM17 (0.71) | ADAM17MMP13MMP8MMP2ALDH1A1 | |
| SCHEMBL8334839 | 0.75 | ADAM17 (1.00) | ADAM17MMP13MMP8MMP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919520-B2 | Inhibitors of tace | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090176782-A1 | INHIBITORS OF TACE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7485664-B2 | Inhibitors of TACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485664-B2 | Inhibitors of TACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176782-A1 | INHIBITORS OF TACE | HDGF, ADAM17, PCSK9 | ADAM17 2/4885MMP13 84/4885MMP8 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.